Bevacizumab抑制高转移性人肝癌原位移植瘤的淋巴管形成  

Bevacizumab inhibited lymphangiogenesis in nude mice with orthotopic metastatic human hepatocellular carcinoma

作　　者：郭子姮[1] 王杰军[1] 于观贞[1] 陈方国[1] 

机构地区：[1]第二军医大学长征医院肿瘤科,上海200070

出　　处：《肿瘤》2006年第8期713-716,共4页Tumor

摘　　要：目的：探讨Bevacizumab抑制肝癌淋巴管形成及抑制肿瘤生长的作用。方法：建立LCI-D20高转移潜能肝癌组织原位移植裸鼠模型,给予治疗剂量的Bevacizumab并设对照组。28d后处死裸鼠,测量肿瘤负荷,免疫组织化学方法检测肿瘤组织微淋巴管密度(lymphatic microvessel density,LMVD)。结果：Bevacizumab治疗组肿瘤负荷低于对照组,统计学上具有显著性差异(P＜0.001)；Bevacizumab治疗组肿瘤内LMVD亦低于对照组,有统计学显著性意义(P＜0.001)。结论：动物实验中,Bevacizumab可有效地抑制肝癌细胞生长和淋巴管形成,为临床治疗肝癌治疗提供新的靶点。Objective：To investigate the inhibitory effects of the anti-vascular endothelial growth factor （VEGF） monoclonal antibody, Becavizumab, on growth and lymphangiogenesis of hepatocellular carcinoma （HCC）. Methods： The model of human hepatocellular carcinoma in nude mice （LCI-D20） with high metastatic potential was established via orthotopic implantation. The nude mice were divided into 2 groups： control group and Bevaeizumab group. The mice in Bevaeizumab group were given thera- peutic dose of Bevaeizumab. Four weeks after the treatment, the nude mice were killed and the tumor load was measured. The lymphatic microvessel density （LMVD） in tumor tissues was detected by immunohistochemical method. Results： Both tumor load and LMVD in Bevaeizumab-treated group were significantly lower than those in control group. The difference was significant （P〈0.001）. Conclusion： Bevacizumab effectively inhibited growth and lymphangiogenesis of liver cancer cells in nude mice, which could provide a new target for treatment of liver carcinoma.

关 键 词：肝肿瘤 肿瘤移植 药物治疗 血管内皮生长因子类/抑制剂 

分 类 号：R735.7[医药卫生—肿瘤]